The Food and Drug Administration yesterday authorized emergency use of a to detect SARS-CoV-2 directly from nasal swab specimens.

Laboratories certified under the Clinical Laboratory Improvement Amendment to perform moderate, high or waived complexity tests and health care providers with a CLIA certificate of waiver, compliance or accreditation may use the test, made by LumiraDx UK Ltd.

Assistant Secretary for Health Admiral Brett Giroir, M.D.,  the novel 鈥渓ow cost鈥 test 鈥渨ill significantly contribute to our scaling up and expanding testing platforms for SARS-CoV-2. This technology has built-in digital connectivity, almost everything we hope for in new testing platforms coming to market. Furthermore, its flexibility to perform diagnostic assays to detect indicators of various diseases, including inflammatory markers, could be transformative in providing improved access to quality health care.鈥

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium鈥
Headline
 The Food and Drug Administration July 10 approved Moderna鈥檚 Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that鈥
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational鈥
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention鈥
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England鈥
Headline
A study published April 8 by the Public Library of Science鈥檚 Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of鈥